EQS Team-News: Relief THERAPEUTICS Holdings AG
/ Essential phrase(s): AGMEGM
Relief Announces Discover of Extraordinary Normal Conference of Relief THERAPEUTICS Keeping AG
23.11.2020 / 07:00
Aid Announces Recognize of Amazing Standard Conference of
Reduction THERAPEUTICS Keeping AG
Geneva, Switzerland, November 23, 2020 – Reduction THERAPEUTICS Keeping AG (Six: RLF, OTCQB: RLFTF) (“Reduction” or the “Enterprise“), a biopharmaceutical company with its guide compound RLF-100TM (aviptadil) in superior medical advancement to treat severe COVID-19 individuals, now gives recognize of an Incredible Common Meeting (EGM) of shareholders to be held on December 17, 2020.
As a outcome of the extraordinary conditions thanks to the coronavirus pandemic, the EGM will be held with out the physical presence of shareholders, reps and third parties in accordance with the needs of the Ordinance of the Swiss Federal Council with regards to actions on combatting the coronavirus. Shareholders are ready to exercise their voting rights by way of offering all voting instructions to the unbiased proxy, Mr. Thomas Hua. Rules on how to produce voting recommendations can be observed in the EGM official invitation, which will be sent out inside of the up coming couple of days to registered shareholders. Guidance transmitted electronically really should be executed no later than December 14, 2020, 23:59 (CET).
Entitlement to vote
Those people shareholders who are registered in the share sign up as of December 4, 2020, 13:00 (CET), are entitled to vote. No registration in the share sign up will be manufactured from December 4 by way of December 17, 2020. Shareholders who market all or portion of their shares prior to the Standard Assembly will no more time be entitled to vote to that extent.
1. Election of the Chair of the Amazing General Assembly
2. Election of Tom Plitz as new member of the Board of Directors
3. Votes on the payment of the associates of the Board of Directors and of the Government Committee
4. Raise of licensed share funds
5. Enhance of conditional share funds 3b2
The entire agenda is readily available for obtain on the Company’s web site (https://relieftherapeutics.com/trader-relations).
Election of Tom Plitz as new member of the Board of Administrators
Tom is Main Executive Officer of Chord Therapeutics SA, a privately held biopharmaceutical firm dependent in Geneva, Switzerland. He has much more than two a long time of working experience in pharmaceutical R&D, most not long ago as Main Scientific Officer of the rare disease organization Wilson Therapeutics. Wilson Therapeutics was obtained for USD 855 million by Alexion Pharmaceuticals in April 2018. Tom’s earlier assignments incorporate senior roles at Serono, Merck, and Shire, where he worked throughout multiple therapeutic regions, which includes neuroinflammatory, metabolic, and unusual health conditions. Tom holds a Ph.D. from Specialized University of Munich, Germany.
Votes on the payment of the customers of the Board of Directors and of the Government Committee
The Board of Directors suggests modifying the compensation pool out there for the remuneration of its customers in the ongoing economical 12 months from CHF 1,000,000 (as earlier accepted by July’s AGM) to CHF 1,500,000. Additionally, with the fast advancement of the Business and its activities over the last months, the Board of Administrators has bolstered, and will proceed to enhance, the Reduction administration workforce. Consequently, a ask for is produced for the acceptance of a payment pool of CHF 5,000,000 for management remuneration for the financial calendar year 2021.
Improve of licensed funds and of conditional share funds 3b2
The authorized share funds is intended for the long run funding of the Business, as needed in connection with potential jobs as very well as for responding quickly to strategic organization prospects. An enhance from 1,056,726,052 shares to 1,250,000,000 shares will deliver the Firm more flexibility to raise capital or go after acquisitions.
An boost of the conditional share capital from 740,329,636 shares to 960,000,000 shares will provide further flexibility need to the Corporation want to use financing instruments with conversion options. This evaluate is being put in position as a precaution and to assure enough funds to finish all examine programs for RLF-100TM. As further more explained in the EGM invitation, the ensuing accessible number of conditional shares will be 340,000,000 shares as current issuances of 620,000,000 new shares out of the conditional share capital 3b2 are not still mirrored in the Posts of Affiliation.
Aid focuses primarily on scientific-phase packages dependent on molecules of normal origin (peptides and proteins) with a heritage of clinical testing and use in human clients or a robust scientific rationale. At present, Reduction is concentrating its endeavours on building new treatments for respiratory condition indications. Its guide drug applicant RLF-100TM (aviptadil), synthetic vasoactive intestinal peptide (VIP), is remaining investigated in two placebo-controlled U.S. Stage 2b/3 scientific trials in respiratory deficiency because of to COVID-19. RLF-100TM is believed to be the initially COVID-19 therapeutic to demonstrate the capacity to block replication of the SARS-CoV-2 virus in human lung cells and monocytes, though also avoiding synthesis of cytokines in the lung. Because July 2020, serious COVID-19 people have been dealt with with RLF-100TM below U.S. Fda Emergency Use Investigational New Drug (IND) authorization and Expanded Accessibility Protocol authorization for the treatment method of respiratory failure in COVID-19.
Reduction also retains a patent issued in the United States and numerous other nations masking likely formulations of RLF-100TM.
Reduction THERAPEUTICS Keeping AG is outlined on the 6 Swiss Exchange less than the symbol RLF and quoted in the U.S. on OTCQB below the symbol RLFTF.
Comply with us on LinkedIn
Get in touch with
Reduction THERAPEUTICS Holding AG
Raghuram (Ram) Selvaraju, Ph.D., MBA
Chairman of the Board
Mail: [email protected]
FOR MEDIA/Trader INQUIRES:
MC Solutions AG
Anne Hennecke / Brittney Sojeva
Mail: [email protected]
Tel.: +49 () 211-529-252-14
Disclaimer: This conversation expressly or implicitly includes selected ahead-looking statements relating to Relief THERAPEUTICS Keeping AG and its enterprise. These kinds of statements entail selected identified and unidentified dangers, uncertainties and other variables, which could result in the real benefits, economical affliction, effectiveness or achievements of Relief THERAPEUTICS Keeping AG to be materially distinctive from any potential final results, performance or achievements expressed or implied by such ahead-looking statements. Relief THERAPEUTICS Holding AG is supplying this conversation as of this date and does not undertake to update any forward-searching statements contained herein as a consequence of new information, upcoming occasions or in any other case.
End of Media Release